About this trial
In neurosurgery both the diffusely infiltrated gliomas of the brain as well as the border towards healthy tissue in the meninges is a challenge. For the high-grade contrast enhanced gliomas fluorescent drugs like Gliolan have been used in several years and proved its clinical value. For non-contrast enhanced gliomas, like low-grade glioma, no such drug exist. The transition zone towards healthy non-tumor cell infiltrated brain in such low-grade gliomas is extremely difficult but for these patients their prognosis depends on the amount of non-healthy tissue left behind. Also, in benign tumors as meningioma the complete resection including infiltrated meninges is of importance for the cure of the disease. None of the existing fluorescent drug is useful or approved for these tumors.. Hence a medicinal product that will fulfil the criteria for a safe and reliable fluorescent drug to guide the surgery to the boundaries of the infiltration with tumor cells is highly warranted.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Subjects diagnosed with primary brain tumor on MRI suggestive of, meningioma or presumed low-grade glioma (pLGG)*
Scheduled for neurosurgery with the objective to remove cancer tissue
Subjects aged 18 years or older
Capable of understanding and giving written informed consent
Disqualifiers
Any known allergy or hypersensitivity to indocyanine green (ICG)
Female subjects who are pregnant or breast-feeding (pregnancy test positive prior to inclusion (or if breast-feeding willing to pause breast feeding during trial and for 30 days
Overall performance status or co-morbidity deeming the subject unfitted for participation in the trial as judged by the Investigator
Pre-existing hepatic and/or renal insufficiency
Trial design
Sequential
Treatments tested in this trial
FG001 prior to surgery
DrugPatients will receive a single intravenous injection of 36 mg FG001 administered the day before surgery.
Treatment groups
Trial outcomes
Primary outcomes
Primary objective
The primary objective is to evaluate the sensitivity of FG001 for detection of tumor tissue from meningioma and pLGG. The sensitivity will be evaluated as the proportion of subjects with fluorescent tumors given the tumor has been histologically verified.
Secondary outcomes
Secondary outcome
The efficacy of FG001 as a tumor imaging agent and safety will be monitored. The efficacy is examined by the sensitivity and specificity. Sensitivity is defined as the probability that a test result is positive when the subject has the disease, while specificity is the probability that a test result is negative when the patient does not have the disease. Safety is determined by physical examinations, laboratory samples and the incidence and severity of the Adverse events (AEs), which are evaluated by National Cancer Institute (NCI) Common Technology Criteria for Adverse Events (CTCAE) version 5.0.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.